IMUX
IMUX
NASDAQ · Biotechnology

Immunic Inc

$1.20
+0.09 (+8.11%)
Financial Highlights (FY 2025)
Revenue
12.96M
Net Income
575.0K
Gross Margin
29.5%
Profit Margin
4.4%
Rev Growth
-0.8%
D/E Ratio
0.71
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 29.5% 29.5% 29.5%
Operating Margin 4.7% 4.7% 5.6%
Profit Margin 4.4% 4.1% 3.5%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 12.96M 11.88M 13.51M
Gross Profit 3.82M 3.50M 3.98M
Operating Income 604.4K 559.6K 758.4K
Net Income 575.0K 486.8K 473.9K
Gross Margin 29.5% 29.5% 29.5%
Operating Margin 4.7% 4.7% 5.6%
Profit Margin 4.4% 4.1% 3.5%
Rev Growth -0.8% +15.7% +3.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 20.71M 27.29M 27.63M
Total Equity 29.20M 26.96M 32.05M
D/E Ratio 0.71 1.01 0.86
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 905.5K 814.6K 969.2K
Free Cash Flow 454.1K 555.8K 696.0K